The
EBC 2026
Copenhagen, Denmark
9th & 10th October
- 00Days
- 00Hrs
- 00Mins
EBC ON-DEMAND
Watch a selection of individual EBC presentations and sessions from previous meetings. For updates and notifications please subscribe to the EBC channel.
EBC Meeting
For more information about the European Bifurcation Club meeting, click the button below.
EBC - Industry Partners
The EBC is gratefully sponsored by medical device, imaging and pharmaceutical
companies specialising in the field of PCI & bifurcation treatments.
Please contact us for more information on how to become a partner of the EBC 2025 meeting:
PLATINUM
We lead global healthcare technology, boldly attacking the most challenging problems. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ people, and our technologies transform the lives of two people every second, every hour, every day. Expect more from us.
Medtronic. Engineering the extraordinary.
GOLD
Interventional Cardiology
From advanced intravascular imaging to lesion preparation and drug-eluting therapies – discover a complete portfolio designed to support informed decisions and optimal patient outcomes.
“Modern PCI means integrating new techniques into a systemic PCI approach that patients understand and physicians can implement” Prof. James Spratt
Our Modern PCI solutions evolve thanks to your input. You inspire us to design a PCI toolkit that equips you with the precision, control, and insights needed to tailor treatment for every coronary lesion.
We are Modern PCI.
From the first guidewire to the first drug-eluting stent, Cordis has been at the heart of cardiovascular innovation for nearly 70 years.
Today, Cordis drives transformation through internal development, Cordis-X partnerships, and strategic acquisitions—powered by a global footprint and deep operational expertise.
With a focus on better clinical outcomes, customer-centered service, and impactful education, Cordis will go beyond to relentlessly pursue its mission to transform cardiovascular care.
Visit our website to learn more
Interventional Cardiology
Terumo’s Interventional Systems division is a global leader in cardiovascular care, providing low invasive devices for the treatment of coronary artery disease. Our philosophy is to deliver high quality devices with unique and innovative technology. We offer a comprehensive device portfolio including products for the diagnosis and treatment of coronary artery disease.
Advanced Bifurcation Systems
ABS announced FDA Breakthrough Device Designation for its bifurcation-stenting technology in 2023. A 13-patient initial feasibility study of the MD-SBA drug-eluting stent system is active and no longer recruiting, with follow-up planned through 2028. In April 2026, ABS announced its acquisition of Svelte Medical Systems’ drug-eluting coronary-stent assets and associated regulatory filings.
Advanced Bifurcation Systems, Inc. (ABS) is a San Francisco Bay Area clinical-stage coronary-device company developing a proprietary stent-delivery platform designed to simplify percutaneous coronary intervention for coronary bifurcation lesions, with a particular focus on left-main anatomy. Its modular Mother–Daughter system uses independently movable dual catheters and is designed to provide automatic orientation and alignment, preserve side-branch access, and support either provisional stenting (ABS MD-SBA) or planned two-stent treatment (ABS MD-BI).
The ABS bifurcation platform remains investigational and is not commercially available. For more information, visit
www.advancedbifurcation.com
SILVER
PARTICIPANT
EDUCATIONAL GRANT
According to EBC consensus documents, it is recommended to perform bifurcation PCI with provisional side branch stenting for the great majority of coronary bifurcation lesions. We recommend a meticulous procedural planning and execution of technical steps that ultimately aim at reconstructing the underlying bifurcation anatomy.